Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYKACET vs CO-GESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Mild to moderate pain,Fever
FDA: Management of moderate to moderately severe pain where an opioid is appropriate.,Off-label: Not commonly used off-label; may be considered for refractory pain conditions.
4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; extended to 12-24 hours in moderate to severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Acetaminophen is extensively metabolized in the liver via conjugation with glucuronic acid (glucuronidation) and sulfuric acid (sulfation). A minor metabolite (N-acetyl-p-benzoquinone imine, NAPQI) is formed via cytochrome P450 isoenzymes (CYP2E1, CYP1A2, CYP3A4) and is primarily detoxified by conjugation with glutathione.
Hydrocodone: primarily hepatic via CYP3A4-mediated N-demethylation to norhydrocodone (active) and O-demethylation via CYP2D6 to hydromorphone (active). Acetaminophen: hepatic via glucuronidation and sulfation; minor oxidation by CYP2E1 to NAPQI (toxic metabolite).
Primarily renal excretion of unchanged drug via glomerular filtration and active tubular secretion; >90% of administered dose appears in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Approximately 20-30% bound to serum proteins, primarily albumin.
<20%; primarily binds to albumin.
Volume of distribution is 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid; does not extensively penetrate tissues or cross the blood-brain barrier.
1.2–1.9 L/kg; suggests extensive distribution into total body water.
Oral bioavailability is approximately 50-70% due to first-pass metabolism; intravenous administration yields 100% bioavailability.
Oral: 85–95%; rectal: 70–80%.
For Cr Cl 20-40 m L/min: 3 g (piperacillin 3 g / tazobactam 0.375 g) q8h; Cr Cl <20 m L/min: 2 g (piperacillin 2 g / tazobactam 0.25 g) q12h.
GFR 30-59 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8 hours; GFR <10 m L/min: Administer every 12 hours; avoid use in severe renal impairment.
No dose adjustment required for hepatic impairment; use standard dosing.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Use not recommended due to hepatotoxicity risk.
For infants >2 months and children <40 kg: 100 mg/kg piperacillin component every 8 hours; for children ≥40 kg: adult dose (4 g q8h).
Children ≥2 years: Hydrocodone 0.1-0.2 mg/kg/dose (max 5 mg/dose) plus acetaminophen 10-15 mg/kg/dose (max 500 mg/dose) orally every 4-6 hours as needed; maximum 5 doses per day.
Adjust dose based on renal function; no specific age-related adjustments beyond renal dosing.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity to opioids and renal clearance decline; monitor for respiratory depression and sedation.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily dose (4 grams/day).
Risk of addiction, abuse, and misuse; serious, life-threatening or fatal respiratory depression from opioid use; accidental ingestion of acetaminophen can cause acute liver failure; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Hepatotoxicity: Risk of acute liver failure with doses exceeding 4g/day, in patients with pre-existing liver disease, or with chronic alcohol use.,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis can occur at any dose.,Hypersensitivity reactions: Anaphylaxis and angioedema.
Addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with concomitant use of CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen overdose); hypersensitivity reactions; constipation; urinary retention; impaired mental/physical abilities.
Hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction (e.g., paralytic ileus); use of MAO inhibitors (concurrent or within 14 days).
Grapefruit juice decreases mycophenolic acid exposure; avoid grapefruit products. High-fat meals reduce absorption; take on empty stomach. Cholestyramine reduces absorption; separate administration by at least 2 hours. Antacids containing magnesium or aluminum should be separated by 2 hours.
Avoid grapefruit and grapefruit juice as they may alter metabolism of hydrocodone. Take with food if gastrointestinal upset occurs. Avoid alcohol-containing foods or beverages. No other significant food interactions.
MYKACET (acalabrutinib) is a BTK inhibitor. In animal studies, embryo-fetal toxicity was observed at maternal exposures below clinical doses. In pregnant women, no adequate data; however, based on mechanism of action, there is potential for fetal harm, particularly during organogenesis (first trimester). Avoid use in pregnancy unless benefit outweighs risk.
First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductus arteriosus and oligohydramnios.
No data on presence in human milk, effects on milk production, or nursing infant. Animal studies show drug and metabolites present in milk. Because of potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for 2 weeks after last dose. M/P ratio: unknown.
No data on M/P ratio; use with caution. Low molecular weight may be excreted into breast milk; monitor infant for sedation or respiratory depression.
No specific dosing recommendations in pregnancy due to lack of data. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may necessitate dose adjustment, but no established guidelines. Use lowest effective dose if unavoidable; monitor for toxicity and efficacy.
No specific dose adjustments required; however, due to increased renal clearance in pregnancy, shortened dosing intervals or higher doses may be needed for adequate analgesia. Monitor clinical response and adjust accordingly.
Mykacet (mycophenolic acid) requires monitoring of complete blood counts due to risk of bone marrow suppression; dose adjustment needed in renal impairment. Avoid concomitant use with azathioprine; administer on empty stomach for consistent absorption. Levels may be affected by cholestyramine or antacids.
Co-Gesic is a fixed-dose combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g. Hydrocodone is a Schedule II controlled substance with abuse potential. Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Avoid concurrent use with other CNS depressants including alcohol. In opioid-tolerant patients, withdrawal may occur if discontinued abruptly.
Take capsules on an empty stomach, 1 hour before or 2 hours after meals.,Do not crush or chew capsules; swallow whole.,Avoid grapefruit juice and other grapefruit products during treatment.,Use effective contraception during and for 6 weeks after stopping therapy due to teratogenic risk.,Report any signs of infection (fever, sore throat) or unusual bruising/bleeding immediately.,Avoid live vaccines; discuss vaccination schedule with your doctor.,Take exactly as prescribed; do not stop without consulting your healthcare provider.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol while taking this medication due to risk of liver damage and increased sedation.,Do not take other medications containing acetaminophen (Tylenol, many cold/flu products) to avoid exceeding the maximum daily dose (4 grams).,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of children and dispose of unused medication properly (take-back programs preferred).,Do not crush or chew extended-release formulations (if applicable).,Report signs of liver injury (yellowing skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYKACET vs CO-GESIC, answered by our medical review team.
MYKACET is a Opioid Analgesic Combination that works by MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.. CO-GESIC is a Opioid Analgesic Combination that works by CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYKACET and CO-GESIC depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYKACET is: 4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.. The standard adult dose of CO-GESIC is: 1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYKACET and CO-GESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYKACET is classified as Category C. MYKACET (acalabrutinib) is a BTK inhibitor. In animal studies, embryo-fetal toxicity was observed at maternal exposures below clinical doses. In pregnant women, no adequate data; h. CO-GESIC is classified as Category C. First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.